Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 1
2017 2
2018 2
2019 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Targeting the arginine metabolic brake enhances immunotherapy for leukaemia.
Mussai F, Wheat R, Sarrou E, Booth S, Stavrou V, Fultang L, Perry T, Kearns P, Cheng P, Keeshan K, Craddock C, De Santo C. Mussai F, et al. Among authors: perry t. Int J Cancer. 2019 Oct 15;145(8):2201-2208. doi: 10.1002/ijc.32028. Epub 2019 Jan 11. Int J Cancer. 2019. PMID: 30485425 Free PMC article. Clinical Trial.
Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma.
Lupino L, Perry T, Margielewska S, Hollows R, Ibrahim M, Care M, Allegood J, Tooze R, Sabbadini R, Reynolds G, Bicknell R, Rudzki Z, Lin Hock Y, Zanetto U, Wei W, Simmons W, Spiegel S, Woodman CBJ, Rowe M, Vrzalikova K, Murray PG. Lupino L, et al. Among authors: perry t. Leukemia. 2019 Dec;33(12):2884-2897. doi: 10.1038/s41375-019-0478-9. Epub 2019 May 16. Leukemia. 2019. PMID: 31097785 Free PMC article.
Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC-subtype diffuse large B-cell lymphoma.
Vockerodt M, Vrzalikova K, Ibrahim M, Nagy E, Margielewska S, Hollows R, Lupino L, Tooze R, Care M, Simmons W, Schrader A, Perry T, Abdullah M, Foster S, Reynolds G, Dowell A, Rudzki Z, Krappmann D, Kube D, Woodman C, Wei W, Taylor G, Murray PG. Vockerodt M, et al. Among authors: perry t. J Pathol. 2019 Jun;248(2):142-154. doi: 10.1002/path.5237. Epub 2019 Mar 22. J Pathol. 2019. PMID: 30666658 Free article.
Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants.
Agathanggelou A, Weston VJ, Perry T, Davies NJ, Skowronska A, Payne DT, Fossey JS, Oldreive CE, Wei W, Pratt G, Parry H, Oscier D, Coles SJ, Hole PS, Darley RL, McMahon M, Hayes JD, Moss P, Stewart GS, Taylor AM, Stankovic T. Agathanggelou A, et al. Among authors: perry t. Haematologica. 2015 Aug;100(8):1076-85. doi: 10.3324/haematol.2014.115170. Epub 2015 Apr 3. Haematologica. 2015. PMID: 25840602 Free PMC article.
USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
Agathanggelou A, Smith E, Davies NJ, Kwok M, Zlatanou A, Oldreive CE, Mao J, Da Costa D, Yadollahi S, Perry T, Kearns P, Skowronska A, Yates E, Parry H, Hillmen P, Reverdy C, Delansorne R, Paneesha S, Pratt G, Moss P, Taylor AMR, Stewart GS, Stankovic T. Agathanggelou A, et al. Among authors: perry t. Blood. 2017 Jul 13;130(2):156-166. doi: 10.1182/blood-2016-12-758219. Epub 2017 May 11. Blood. 2017. PMID: 28495793 Free article.
The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts.
Williams MT, Yousafzai YM, Elder A, Rehe K, Bomken S, Frishman-Levy L, Tavor S, Sinclair P, Dormon K, Masic D, Perry T, Weston VJ, Kearns P, Blair H, Russell LJ, Heidenreich O, Irving JA, Izraeli S, Vormoor J, Graham GJ, Halsey C. Williams MT, et al. Among authors: perry t. Blood. 2016 Apr 21;127(16):1998-2006. doi: 10.1182/blood-2015-08-665034. Epub 2016 Feb 11. Blood. 2016. PMID: 26869395 Free article.
11 results